{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-22-000043","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.202656+00:00","generated_at":"2026-06-22T04:18:02.620316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Royalty Pharma Q3 2022: Adjusted Cash Receipts up 2% to $597M; raises FY 2022 guidance to $2,750-2,800M","bullets":["Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).","Raised FY 2022 Adjusted Cash Receipts guidance to $2,750-2,800M, including $458M from Pfizer's Biohaven acquisition acceleration.","Announced up to $3.0B YTD capital deployment, including R&D funding collaboration with Merck (MK-8189).","Royalty receipts: Cystic fibrosis franchise $208M (+14%), Trelegy added $43M, Januvia/Janumet down 97% to $1M.","Adjusted EBITDA $548M (+3%); operating costs 8% of Adjusted Cash Receipts."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-22-000043","json":"https://secwatch.observer/filing/0001802768-22-000043.json","markdown":"https://secwatch.observer/filing/0001802768-22-000043.md","text":"https://secwatch.observer/filing/0001802768-22-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/0001802768-22-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/rprx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:18:02.620316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0850a15df83c88237699c688ff3d190bae65475b","claim":"Royalty Pharma plc updated its the third quarter of 2022 guidance (raised).","evidence_excerpt":"On November 8, 2022, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/0001802768-22-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}